-
Mashup Score: 0Biosimilars Month in Review: April 2024 - 4 hour(s) ago
The biosimilars month in review reflects ongoing efforts to address key challenges in rheumatic disease treatment.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Amjevita leads Humira biosimilars in clinician comfort as rheumatologists remain wary - 17 day(s) ago
Only half of rheumatologists are “extremely comfortable” prescribing the Humira biosimilar Amjevita, while just 16% can say the same for all other adalimumab biosimilars combined, according to a market analysis from Spherix Global Insights. For reference, 83% of rheumatologists included in the analysis reported being “extremely comfortable” prescribing originator Humira
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 0Amjevita leads Humira biosimilars in clinician comfort as rheumatologists remain wary - 22 day(s) ago
Only half of rheumatologists are “extremely comfortable” prescribing the Humira biosimilar Amjevita, while just 16% can say the same for all other adalimumab biosimilars combined, according to a market analysis from Spherix Global Insights. For reference, 83% of rheumatologists included in the analysis reported being “extremely comfortable” prescribing originator Humira
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 09 Biosimilars for Intravitreal nAMD, DME Treatment - 24 day(s) ago
A number of biosimilar options to treat the common retina diseases are in development globally. Here’s a highlight of 9 with supporting late-stage data.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 4
In a review, investigators focused on ranibizumab (Lucentis; Genentech), aflibercept (Eylea; Regeneron), and bevacizumab (Avastin; Genentech) as growth opportunities in the biosimilar space.
Source: www.pharmacytimes.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 6
The results indicate the need for targeted policies so that biosimilar competition can increase cost savings and affordability for patients with commercial insurance.
Source: www.pharmacytimes.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 2
The phase 2b trial showed a statistically significant improvement of BCVA at week 52 in both the high-dose and low-dose MCO-010 cohorts compared with sham.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2
The decision was based on clinical studies demonstrating no clinically meaningful differences between the biosimilar and its reference product.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3Biosimilars 102: Interchangeability, Extrapolation, and Immunogenicity -- A Regulatory Process Primer - 2 month(s) ago
How much do you know about biosimilars and how they are regulated? Find out in this informative article.
Source: www.medscape.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Originator Users in Finland Hesitant on Using Biosimilars - 3 month(s) ago
Nearly half (47%) of biosimilar users knew they were using biosimilars but 31% thought the medicine was an originator. In contrast, 80% of originator users knew they were using an originator, and none thought they were using a biosimilar.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
The #biosimilars month in review reflects ongoing efforts to address key challenges in rheumatic disease treatment. Check it out here: https://t.co/ax2mvDFCQW